{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:50:57Z","timestamp":1779886257148,"version":"3.53.1"},"reference-count":84,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) represents a hematological neoplasia with an uncontrolled proliferation of malignant plasma cells and complex cytogenetic abnormalities. t(11;14) has emerged as a crucial genetic aberration and is one of the most common primary translocations in MM. Patients harboring t(11;14) represent a distinctive subgroup with a clinical profile that differs from t(11;14)-negative MM risk categories. One of the key features linked with t(11;14) is the BCL2 dependency, indicating vulnerability to BCL2 inhibition. BCL2 inhibitors, such as venetoclax, demonstrated impressive efficacy alone or in combination with other anti-myeloma drugs in patients with RRMM accompanied by t(11;14) and BCL2 overexpression. Therefore, t(11;14) plays a key role in both risk stratification and informed decision making towards a tailored therapy. In this review, we highlight the biology of t(11;14) in MM cells, summarize the current evolving role of t(11;14) in the era of novel agents and novel targeted therapies, illuminate current efficacy and safety data of BCL2-based treatment options and explore the future prospects of individualized precision medicine for this special subgroup of patients with MM.<\/jats:p>","DOI":"10.3390\/cancers15245829","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:00:37Z","timestamp":1702468837000},"page":"5829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-4753","authenticated-orcid":false,"given":"Martina","family":"Kleber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Clinic Hirslanden Zurich, 8032 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Giannakoulas, N., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094462"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2021.01.018","article-title":"Real-World Treatment of Patients with Relapsed\/Refractory Myeloma","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Paiva","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: A single-center experience over 20-year period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas\u2014Current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.26639","article-title":"Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications","volume":"97","author":"Kastritis","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: Association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clml.2019.10.014","article-title":"Early Relapse after Autologous Transplant Is Associated with Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients with Myeloma","volume":"20","author":"Kastritis","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2013.05.017","article-title":"Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma","volume":"19","author":"Sasaki","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/leu.2017.204","article-title":"Natural history of t(11;14) multiple myeloma","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: A promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.33206","article-title":"Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?","volume":"127","author":"Chakraborty","year":"2021","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/bjh.17627","article-title":"Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma","volume":"195","author":"Bal","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) Abnormality on Outcomes of Patients with Newly Diagnosed Multiple Myeloma in the Connect MM Registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/gcc.22372","article-title":"Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?","volume":"55","author":"Leiba","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_28","first-page":"2950","article-title":"Multiple myeloma with t(11;14): Unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000508234","article-title":"Ageism in the t(11;14) Subtype of Multiple Myeloma","volume":"144","author":"Gonsalves","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Facon","year":"2002","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2021011452","article-title":"IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM","volume":"138","author":"Bazarbachi","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/10428199909169625","article-title":"Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma","volume":"35","author":"Fonseca","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): Consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14656566.2021.1999411","article-title":"Nonselective proteasome inhibitors in multiple myeloma and future perspectives","volume":"23","author":"Gavriatopoulou","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ejh.13993","article-title":"Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies","volume":"111","author":"Fotiou","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"934008","DOI":"10.3389\/fonc.2022.934008","article-title":"Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation","volume":"12","author":"Diamantidis","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1242\/jcs.031682","article-title":"Control of mitochondrial apoptosis by the Bcl-2 family","volume":"122","author":"Brunelle","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: Pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1182\/blood-2022-163809","article-title":"An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1\/2 Study of Patients with t(11;14) Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Kaufman","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A Phase II Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"TPS8554","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554","article-title":"A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma","volume":"38","author":"Mateos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_58","unstructured":"Mateos, M.V. (2023, January 27). Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients with t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma. Proceedings of the 20th International Myeloma Workshop 2023, Abstract OA-52, Athens, Greece."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2021-145757","article-title":"Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S2152-2650(23)01596-3","article-title":"OA-29 First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed\/refractory multiple myeloma","volume":"23","author":"Kaufman","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14712598.2020.1717464","article-title":"Antibody therapies for multiple myeloma","volume":"20","author":"Gavriatopoulou","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, with or without Bortezomib, in Patients with Relapsed or Refractory Multiple Myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1002\/ajh.26064","article-title":"Natural history of multiple myeloma patients refractory to venetoclax: A single center experience","volume":"96","author":"Maples","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2021-150370","article-title":"Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma","volume":"138","author":"Dai","year":"2021","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2019-127593","article-title":"Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients","volume":"134","author":"Neri","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.exphem.2008.01.003","article-title":"R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells","volume":"36","author":"Kline","year":"2008","journal-title":"Exp. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.12633","article-title":"AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia","volume":"164","author":"Paulus","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2021.39.15_suppl.7502","article-title":"First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs)","volume":"39","author":"Ailawadhi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2021-148451","article-title":"Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed\/Refractory (R\/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1182\/blood-2022-169666","article-title":"Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed\/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b\/2 Study","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Patterson, C.M., Balachander, S.B., Grant, I., Pop-Damkov, P., Kelly, B., McCoull, W., Parker, J., Giannis, M., Hill, K.J., and Gibbons, F.D. (2021). Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun. Biol., 4.","DOI":"10.1038\/s42003-020-01631-8"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Robillard","year":"2005","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14251","article-title":"BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma","volume":"179","author":"Dousset","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clml.2019.09.081","article-title":"A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients with Relapsed or Refractory Multiple Myeloma","volume":"19","author":"Spencer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jphp.13240","article-title":"Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma","volume":"72","author":"Wong","year":"2020","journal-title":"J. Pharm. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:38:13Z","timestamp":1760132293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":84,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245829"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245829","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}